Active · per the CBE, 17 November 2026

PharmaLex Belgium

BE0667829063

Rechtspersoon Public limited company 2 establishments

PharmaLex Belgium is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Public Limited, started on 19 December 2016, 2 establishments.

Weiveldlaan 3 box 5, 1930 Zaventem

Active for

9 year, 10 months

Warning lights

Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.

  • Late annual account NBB

    Fiscal year 2024 was filed 476 days after the legal deadline.

  • Annual account missing NBB

    Fiscal year 2025 was expected before 30 April 2026 and has not been filed.

Financials

Financial year 2024

PharmaLex Belgium from Zaventem, company number BE0667829063, closed financial year 2024 with a result of € -102,323 after tax. For that financial year PharmaLex Belgium recorded revenue of € 8.4 million and equity of € 2.4 million. Compared with financial year 2023, the result moved from € 577,668 to € -102,323. The company made a loss. The company holds a healthy buffer. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on August 19, 2026.

What it is worth Healthy

€ 2.4 million

▼ 4% vs 2023

Assets minus debts, by the books. What is left if everything were sold and paid today.

Loss Caution

€ -102,323

▼ still € 577,668 profit in 2023

Profit after tax over the fiscal year.

Cash in the bank

€ 1.1 million

▼ 45% vs 2023

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Caution

Loss, nothing to pay out

Reserves fell to € 2.2 million.

People and assets in 2024

Full-time equivalents

47.1

▼ 2.9 vs 2023

Average over the fiscal year, from the social balance sheet.

Wage cost

€ 4.7 million

▲ 19% vs 2023

€ 100,100 per full-time equivalent. Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.

Vehicles and equipment

€ 107,157

▲ 51% vs 2023

Of which on lease € 3,448.

Debts at end 2024

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 892,742

▼ 5% vs 2023

Supplier invoices still open on the last day of the fiscal year. Pays suppliers within 84 days on average.

Taxes and wages

€ 806,194

▼ 52% vs 2023

Taxes, VAT and social contributions still to pay.

Key figures per fiscal year
2021202220232024Change 2023 → 2024
Revenue € 4,637,220 € 5,736,800 € 6,993,437 € 8,370,817 ▲ 20%
Gross margin € 2,849,403 € 3,478,095 - -
Profit after taxes € 419,825 € 559,419 € 577,668 € -102,323 ▼ € 679,991
Equity € 926,251 € 1,335,670 € 2,461,420 € 2,359,097 ▼ 4%
Total debts € 1,701,611 € 2,377,180 € 3,334,192 € 2,539,376 ▼ 24%
Cash € 173,617 € 399,948 € 1,922,780 € 1,066,696 ▼ 45%
Retained profit € 826,251 € 1,235,670 € 2,342,820 € 2,240,497 ▼ 4%
Dividend € 100,000 € 150,000 € 0 € 0
Bank debt € 5,491 € 2,591 € 0 € 0
Balance sheet total € 2,627,862 € 3,712,850 € 5,871,467 € 4,974,328 ▼ 15%
Employees (FTE) 25.6 28.5 50 47.1 ▼ 2.9

By revenue, PharmaLex Belgium ranks 13th of 26 companies with main activity “Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies” in Zaventem that publish figures (fiscal year 2024).

Key figures of PharmaLex Belgium, fiscal years 2021 to 2024, from the annual accounts filed with the National Bank of Belgium.The annual account for fiscal year 2025 has not been filed yet; it was expected before 30 April 2026.

What happened to PharmaLex Belgium?

What happened at PharmaLex Belgium in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

  • Anne Peeters stepped down as director. NBB
  • Christopher Gauglitz stepped down as director. NBB
  • Pharmalex France SAS stepped down as director. NBB
  • Capital increase of € 2.2 million, published in the Gazette. Source: Staatsblad ↗
  • New annual accounts for financial year 2024: loss of € 102,323 (▼ € 679,991 vs 2023). filed late Source: NBB ↗
  • Anne Peeters became a director. NBB
  • Christopher Gauglitz became a director. NBB
  • Pharmalex France SAS became a director. NBB

In short

From € 419,825 profit in 2021 to € 102,323 loss in 2024.

Paid € 539,676 in corporate taxes since 2021.

Best year ever: 2023, with € 577,668 profit.

On average € 122,000 of value added per employee in 2022.

Management

AmerisourceBergen International B.V. 100%
PharmaLex Belgium

The shares are held by AmerisourceBergen International B.V. (100%).

Directors

According to the 2024 annual accounts

Anne Peeters

Director

since 2024 · until 2030

Christopher Gauglitz

Director

since 2024 · until 2030

Pharmalex France SAS

Director · represented by Åsa Pihlblad

since 2024 · until 2030

Shareholders

AmerisourceBergen International B.V.

100%

Participations

No participations in other companies reported.

Establishments

Establishment units

Physical locations of this company

Registered office

Weiveldlaan 3 box 5

1930 Zaventem

2.260.918.560

Rue Edouard Belin 5

1435 Mont-Saint-Guibert

Active since 19 December 2016

2.352.876.441

Weiveldlaan 3/5

1930 Zaventem

Active since 1 August 2023

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Similar companies in Zaventem

Same main activity (Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies), 198 active companies in Zaventem, largest first.

Deloitte Consulting & Advisory

€ 583.5 million revenue · 2023

KPMG ADVISORY

€ 96.9 million revenue · 2025

Indovinya Belgium

€ 73.2 million revenue · 2025

GRAPHIC PACKAGING INTERNATIONAL EUROPE

€ 63.8 million revenue · 2024

TSL BE

€ 60.3 million revenue · 2025

BDO BELGIUM

€ 45.8 million revenue · 2025

Shareholders according to the Official Gazette deeds

Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.

Incorporation

Source: Deed ↗
  • PharmaLex GmbH(oprichter) 100%
  • PharmaLex Holding GmbH(oprichter) 0%

Details

Company number
0667.829.063
VAT number
BE 0667.829.063
Registered office
Weiveldlaan 3 bus 5, 1930 Zaventem
Names & denominations
PharmaLex Belgium
Enterprise type
Rechtspersoon
Legal form
Public limited company
Legal situation
Normale toestand
Start date
19 December 2016
Peppol
Active · Active since 10 Dec 2025
Activities · NACE

Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies

Overige adviesbureaus op het gebied van bedrijfsbeheer; adviesbureaus op het gebied van bedrijfsvoering

Overige dienstverlenende activiteiten op het gebied van informatie

Overige dienstverlenende activiteiten op het gebied van informatie, n.e. g.

Frequently asked questions

What does PharmaLex Belgium do?
PharmaLex Belgium is registered with the CBE as active in: Activiteiten van adviesbureaus op het gebied van bedrijfsvoering en overig managementadvies. Public Limited, started on 19 December 2016, 2 establishments.
What is the address of PharmaLex Belgium?
The registered office of PharmaLex Belgium is located at Weiveldlaan 3 box 5, 1930 Zaventem.
Is PharmaLex Belgium still active?
Yes. According to the CBE (17 November 2026) PharmaLex Belgium is active, legal situation “Normale toestand”, started on 19 December 2016.
Is PharmaLex Belgium registered on Peppol?
Yes, PharmaLex Belgium is registered on the Peppol network with ID 0208:0667829063.
What is the enterprise number of PharmaLex Belgium?
The enterprise number of PharmaLex Belgium is BE0667829063.
When was PharmaLex Belgium founded?
PharmaLex Belgium was founded on 19 December 2016.